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Background: The aim of this study was to evaluate the calibration and discriminatory power of three predictive
models of breast cancer risk.
Methods: We included 13,760 women who were first-time participants in the Sabadell-Cerdanyola Breast Cancer
Screening Program, in Catalonia, Spain. Projections of risk were obtained at three and five years for invasive cancer
using the Gail, Chen and Barlow models. Incidence and mortality data were obtained from the Catalan registries.
The calibration and discrimination of the models were assessed using the Hosmer-Lemeshow C statistic, the area
under the receiver operating characteristic curve (AUC) and the Harrell’s C statistic.
Results: The Gail and Chen models showed good calibration while the Barlow model overestimated the number of
cases: the ratio between estimated and observed values at 5 years ranged from 0.86 to 1.55 for the first two models
and from 1.82 to 3.44 for the Barlow model. The 5-year projection for the Chen and Barlow models had the highest
discrimination, with an AUC around 0.58. The Harrell’s C statistic showed very similar values in the 5-year projection
for each of the models. Although they passed the calibration test, the Gail and Chen models overestimated the
number of cases in some breast density categories.
Conclusions: These models cannot be used as a measure of individual risk in early detection programs to
customize screening strategies. The inclusion of longitudinal measures of breast density or other risk factors in joint
models of survival and longitudinal data may be a step towards personalized early detection of BC.
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It is estimated that, in the year 2015, 21,000 women in
Spain will be diagnosed with breast cancer (BC), repre-
senting 25% of all cancers among women [1]. BC is the
cancer that results in the greatest global mortality
among women (268,000 deaths, 12.7% of all deaths) [1].
Given that the majority of known risk factors for BC are
not modifiable, population-based primary prevention
programs do not exist. As a consequence, early detec-
tion is a priority among public health programs, with
the goal of improving disease prognosis and reducing* Correspondence: mbare@tauli.cat
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reproduction in any medium, provided the ormortality. Early detection or screening programs, together
with the development of new adjuvant treatments, have
contributed to the reduction in mortality associated with
BC [2,3].
Currently, age and gender are the only criteria for de-
fining the target population to be screened. Nevertheless,
it has been reported that age at first birth, family history
of BC, mammographic density or genetic factors are also
associated with greater risk [4,5]. Having a reliable indi-
vidual BC risk estimate based on known factors makes it
possible to develop personalized screening programs and
optimize the use of resources in a population.
Taking individual risk into account in screening strategies
is new. In the USA, the National Cancer Institute started
an initiative, the Cancer Intervention and Surveillance
Modeling Network (CISNET), with the goal of evaluatingral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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BC incidence and mortality [6-8]. Recently, in a cost-
effectiveness study, Schousboe et al. [9] have proposed
different screening periodicities based on BC risk,
measured as a function of breast density, family history
of BC and previous breast biopsy.
The estimate of BC risk has been the subject of the
publication of several articles in recent decades. The
model created by Gail et al. in 1989 is, without doubt,
the most widely known and used up to this point for the
prediction of BC [10]. Furthermore, this model has been
the reference for other models developed more recently.
The modification of the Gail model, by including breast
density and the weight of the woman as risk factors, led
to the model developed by Chen, et al. [11]. The model
described in 2006 by Barlow, et al. [12] takes into account,
in addition to breast density, factors such as hormone re-
placement therapy, body mass index, race or ethnicity,
which had not been previously incorporated into models
as predictive variables. There are other models that either
estimate the risk of carrying mutations in the BRCA1
or BRCA2 genes or use the information on BRCA1/2
status to improve the estimates of BC risk. Models like
BRCAPRO [13] or the Tyrer-Cuzick [14] model are
primarily based on family history of breast and ovarian
cancer.
The generalized use of risk models requires that they
be previously validated in different populations, given
the possible differences in the distribution of risk factors
and in the epidemiology of BC. Once external validity is
verified, personalized screening strategies based on risk
can be designed with the aim of improving the efficiency
of screening programs. The principal objective of this
study was to evaluate the calibration and discriminatory
power of predictive models of BC risk, without genetic
information, in a cohort of women in a Spanish early
detection program.
Methods
This is a validation study of the main models developed
for estimating the risk of BC for women not at high risk.
The selected models were identified from the published
literature. We included 13,760 women that participated
for the first time in the BC early-detection program in
the Sabadell-Cerdanyola (EDBC-SC) area in Catalonia
(Spain), between October 1995 and June 1998. The par-
ticipants did not have a personal history of BC and were
followed for vital status or possible diagnosis of BC
until July of 2010 [15,16]. The EDBC-SC screening
program offers biennial mammography for women aged
50 to 69. The data for this study were obtained through
a questionnaire administered on the first visit, which
included demographic variables, weight and height, per-
sonal gynecological history and family history of BC.Moreover, as a remarkable and unique characteristic
among the Spanish BC screening programs, breast density
was recorded on each mammographic test and rated ac-
cording to the Breast Imaging Reporting and Data System
(BI-RADS) [17]. Of the 13,760 women interviewed, we ex-
cluded seven without follow-up data, as well as 29 women
who were diagnosed with BC and 15 who died within
6 months of baseline. We analyzed incident invasive can-
cers diagnosed at any time during follow-up, whether the
diagnosis was made within the program or took place out-
side of it [16]. The final sample included 13,709 women,
with 329 diagnosed with invasive BC.
Description and changes on the selected models
The models selected for evaluation were developed by
Gail [10], Chen [11] and Barlow [12]. The Gail and
Chen models have an identical structure. They estimate
the risk of developing BC over time using three compo-
nents: 1) age-specific relative risks for selected risk factors,
2) incidence of BC in a baseline study population, and
3) competing risks of death.
The original Gail model included both ductal carcinoma
in situ (DCIS) and invasive BC. A few years later the inci-
dence rates were modified with the objective of using the
model for invasive BC only [18,19]. Chen and Barlow con-
sidered only invasive BC in their respective models. Since
the selected models, except the initial Gail model, were
developed to predict the risk of invasive BC, in this study
we have considered only invasive BC. We customized the
Gail and Chen models using an estimated incidence func-
tion of invasive BC in Catalonia. Women diagnosed with
DCIS in our study cohort were not excluded from the ana-
lysis, they were considered at risk of developing invasive
BC.
To obtain the baseline BC risk of the study population,
required for the Gail and Chen models, BC incidence
was multiplied by the complement of the attributable
risk (1-AR) corresponding to the distribution of risk
factors in the study sample. The AR calculation was
performed as described in Chen et al. [11]. We used
the relative risks of the covariates that were estimated
when the models were developed. Since the AR varied
little with age, it was considered a constant value for
the whole range of ages. The estimated AR for the Gail
model was 0.369, and for the Chen model, 0.805. The
difference in AR between the Gail and Chen models
was due to the fact that the Chen model includes breast
density and therefore the baseline risk is considerably
lower.
Incidence data for invasive BC were obtained from the
Girona and Tarragona Cancer Registries. Incidence rates
for the observed period and projected rates for subsequent
years were estimated using an age-cohort model with age
as a fourth degree and cohort as quadratic polynomials
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population were obtained from the Mortality Registry of
the Catalan Department of Health (see Additional file 1:
Table S1). The mortality rates from causes other than
BC, by age and cohort, were obtained from Vilaprinyó
et al. [20].
To estimate the relative risks of BC, the Gail model
takes into account the number of first degree relatives
with a history of BC, age at first live birth, age at menarche
and the number of previous benign biopsies. The Chen
model also includes breast density and weight, but unlike
the initial Gail model does not include the age at menar-
che or interactions. The Barlow model includes breast
density, hormone replacement therapy, body mass index,
result of previous mammography exams, race and ethni-
city as risk factors. For the Barlow model, the projected
risk of BC was based on two separate logistic regression
models, one for pre-menopausal women and the other for
postmenopausal women.
Projections of risk were obtained at 3 and 5 years,
starting six months after the first screening mammo-
gram. Although most of the studies in the literature have
worked with five years of follow-up, we considered that
projection at 3-years would be useful for short-term
decision-making on screening. For the Barlow model,
which was designed to estimate the risk of developing
invasive BC in a period of one year, the original article
recommends projecting the risk for longer periods as-
suming that the probability of developing BC is identical
and independent in each of the ensuing years [12]. Risk
estimates for the three models were obtained using
Mathematica [21].Statistical analysis
We performed a descriptive analysis of the studied vari-
ables. Characteristics of women in relation to BC diagnosis
were compared using the chi-square test or the Fisher’s
exact test for dichotomous variables.
The calibration of the models was assessed using the
Hosmer-Lemeshow goodness-of-fit C statistic [22]. The
C statistic compares the observed (O) and expected (E)
number of BC cases by risk quantiles. The expected
number of cases was obtained by adding the probabil-
ities estimated by the models for each woman in the
group. First, calibration was assessed by quintiles of
risk, for the 3 and 5-year projections. Although deciles
are often used, we considered that quintiles were more
appropriate, given the small number of cancer cases.
Then, for the 5-year projections, calibration was assessed
on groups determined by categories of risk factors. Trends
in the E/O ratio by categories of risk were assessed using
the chi-square test for trends in order to search for sub-
groups in which the models worked the best.The model’s discrimination was assessed using the
Harrell C statistic, which measures the proportion of all
patient pairs in which the predicted breast cancer prob-
ability and the follow-up interval (or time to event if the
final event occurs), are ranked equally [23,24]. This con-
cordance measure is a modification of the area under
the receiver operating characteristic curve (ROC) that
we also included in order to compare our results with
similar studies. For these analyses we used the Stata/SE
software [25].
Results
Table 1 shows the main characteristics of the studied
women. The mean age was 57.0 years and 94.4% of them
were postmenopausal. The 18.6% of the women in the
study had their first menstrual period before age 12 and
the 46.6% of women had their first child at ages between
20 and 24 years. In the study sample, 7.9% of women
who subsequently developed invasive BC had first-
degree relatives with BC while this percentage was 5.3%
in women who had not developed BC. This difference
was not statistically significant. However, the differences
in breast density, age at first mammogram and previous
benign breast disease were significant. Many women re-
ported having previous benign breast disease with no
previous biopsy. This was not an unusual practice, in the
past, in our publicly funded health system.
Median follow-up time was 13.3 years with an inter-
quartile range of 12.7-13.9 years.
Validation of the Gail, Chen and Barlow models
The Gail and Chen models showed good calibration, at
3- and 5-years, with similar expected and observed num-
ber of cases and p-values >0.05 for the Hosmer-Lemeshow
C statistics (Table 2). Conversely, the Barlow model over-
estimated the number of cases, with ratios E/O above 1.8
in all the quintiles of risk and values above 3.3 in the
upper quintiles.
When comparing the means of the estimated risk values
by BC diagnosis, there were statistically significant differ-
ences in the three models at 5-years, but not at 3-years
(Table 3).
The studied risk models showed poor discrimination
in the study sample. The areas under the receiver oper-
ating characteristic curve (AUC) ranged from 0.52 to
0.59. For the Gail’s model, the AUC confidence intervals
for the 3- and 5-year projections included the value
0.50, which indicates the absence of discrimination. The
Chen and Barlow models had higher discrimination at
five years, with AUCs around 0.58, whereas the Gail
model had an AUC around 0.56 in both the 3- and 5-
year projections.
When time to BC diagnosis was taken into account, the
Harrell C statistic indicated that the 5-year projection for
Table 1 Characteristics of the study sample
No cancer(1) (N = 13380) Cancer (N = 329) Total (N = 13709)
N % N % N % p-value(3)
Age at first mammogram, y 50-54 4975 37.18 120 36.47 5095 37.17 0.026
55-59 3602 26.92 110 33.43 3712 27.08
60-64 4216 31.51 83 25.23 4299 31.36
65-69 587 4.39 16 4.86 603 4.40
Age at menarche, y <12 2493 18.63 62 18.84 2555 18.64 0.990
12-13 5243 39.19 129 39.21 5372 39.19
> = 14 5505 41.14 134 40.73 5639 41.13
Unknown 139 1.04 4 1.22 143 1.04
Age at first live birth, y <20 1065 7.96 26 7.90 1091 7.96 0.050
20-24 6242 46.65 151 45.90 6393 46.63
25-29 4109 30.71 91 27.66 4200 30.64
>29 966 7.22 37 11.25 1003 7.32
No children 902 6.74 23 6.99 925 6.75
Unknown 96 0.72 1 0.30 97 0.71
Body mass index <25 3347 25.01 92 27.96 3439 25.09 0.569
25-29 4519 33.77 105 31.91 4624 33.73
30-34 1944 14.53 53 16.11 1997 14.57
> = 35 675 5.04 16 4.86 691 5.04
Unknown 2895 21.64 63 19.15 2958 21.58
Breast density (BI-RADS)(2) 1 2969 22.19 50 15.20 3019 22.03 <0.001
2 5378 40.19 102 31.00 5480 39.98
3 2338 17.47 83 25.23 2421 17.65
4 2067 15.45 73 22.19 2140 15.63
Unknown 628 4.69 21 6.38 649 4.73
No. of biopsies 0 13263 99.13 325 98.78 13588 99.12 0.513
> = 1 117 0.87 4 1.22 121 0.88
Menopausal status No 747 5.58 18 5.47 765 5.58 0.930
Yes 12633 94.42 311 94.53 12944 94.42
Affected first-degree relatives No 12647 94.52 302 91.79 12949 94.46 0.195
Yes 704 5.26 26 7.90 730 5.32
Unknown 29 0.22 1 0.30 30 0.22
Previous benign breast disease No 12420 92.83 292 88.75 12712 92.73 0.005
Yes 960 7.17 37 11.25 997 7.27
(1)Ductal carcinoma in situ cases were included as no cancer cases.
(2)1: Almost entirely fat, 2: Scattered fibroglandular densities, 3: Heterogeneously dense, 4: Extremely dense.
(3)P-values have been obtained excluding the unknown values.
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women in the study. The 5-year projection for the Barlow
and Chen models increased this figure to 57.5% and
58.6%, respectively (Table 3).
Table 4 shows the calibration by categories of the risk
factors in the studied models. As before, the Gail and
Chen models showed good calibration, except for age at
first mammogram where the E/O ratio fluctuated. The
Barlow model overestimated the number of BC casesand no trends were observed in the categories of the risk
factors. By age groups, both the Gail and Chen models
overestimated the number of cases in women 50–54 and
60–64 and underestimated them in women 65 years old
or older. With regard to breast density, although the
Gail and Chen models passed the calibration tests, the
Gail model overestimated the number of cases in women
with breast densities 1 and 2 and the Chen model in
women with breast density 4.
Table 2 Calibration of the risk models by quintiles of risk
N Expected cases (E) Observed cases (O) E/O C Hosmer-Lemeshow statistic p-value
Gail model
3-year 1 2569 10 9 1.11
2 2894 13 14 0.93
3 2656 13 12 1.08
4 2740 16 11 1.45
5 2587 20 17 1.18 2.28 0.516
5-year 1 2671 17 16 1.06
2 2705 21 22 0.95
3 2612 22 16 1.38
4 2742 27 18 1.50
5 2716 37 35 1.06 4.90 0.180
Chen model
3-year 1 2524 7 11 0.64
2 2420 9 7 1.29
3 2513 12 13 0.92
4 2498 15 15 1.00
5 2479 22 14 1.57 5.76 0.124
5-year 1 2423 12 14 0.86
2 2519 17 11 1.55
3 2495 21 21 1.00
4 2511 26 23 1.13
5 2487 39 28 1.39 5.97 0.113
Barlow model
3-year 1 2713 19 8 2.38
2 2722 29 13 2.23
3 2716 39 10 3.90
4 2804 50 13 3.85
5 2754 70 19 3.68 103.22 < 0.001
5-year 1 2713 31 17 1.82
2 2847 51 18 2.83
3 2591 62 18 3.44
4 2833 84 20 4.20
5 2725 115 35 3.29 168.49 < 0.001
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The principal result of this study is that when adapting
the incidence and mortality rates, the Gail and Chen
models were well calibrated to estimate the risk of inva-
sive BC in a population of Spanish women who partici-
pated in a screening program, whereas the Barlow
model significantly overestimated this risk. All the three
predictive models show a limited level of discrimin-
ation, despite the fact that they have been previously
used in the US to classify women into high and low risk
groups [18]. In general, good performance was seen in theGail and Chen models when the subgroups of women are
defined by categories of risk factors.
It is relevant to point out that the use of these models
in our study reproduces the original results in terms of
discrimination. In the original article, Chen et al. already
compared the discriminatory value of the Gail model
against a new model that included breast density. In that
case, the AUC for the 5-year prediction was 0.596 for
the Gail model and 0.643 for the Chen model [11]. In
general, it is considered that a prediction tool should
have an AUC greater than 0.7 [22]. With adaptation to
Table 3 Means of the probabilities of developing breast cancer and discriminatory power of the models
Gail model Chen model Barlow model
3-year No cancer 0.005340 0.005320 0.015089
Cancer 0.005728 0.005624 0.015514
p-value 0.100 0.354 0.648
AUC 0.562 (0.481, 0.644) 0.523 (0.441, 0.604) 0.526 (0.448, 0.603)
C-Harrell 0.562 (0.481, 0.643) 0.523 (0.442, 0.603) 0.526 (0.449, 0.603)
5-year No cancer 0.009226 0.009185 0.024974
Cancer 0.010014 0.010723 0.028571
p-value 0.011 < 0.001 0.002
AUC 0.561 (0.499, 0.623) 0.586 (0.526, 0.646) 0.575 (0.513, 0.638)
C-Harrell 0.561 (0.480, 0.642) 0.586 (0.526, 0.645) 0.575 (0.513, 0.637)
Table 4 Calibration of the risk models by categories of the risk factors
Gail model Chen model Barlow model
N Observed
cases (O)
Expected
cases (E)
E/O p-value(2) Expected
cases
E/O p-value(2) Expected
cases
E/O p-value(2)
Age at first mammogram, y 50-54 5095 31 42 1.35 0.009 41 1.32 0.006 99 3.19 < 0.001
55-59 3712 34 33 0.97 31 0.91 97 2.85
60-64 4299 30 42 1.40 37 1.23 128 4.27
65-69 603 13 7 0.54 6 0.46 19 1.46
Age at menarche, y <12 2555 25 25 1.00 0.364 21 0.84 0.552 61 2.44 < 0.001
12-13 5372 39 50 1.28 45 1.15 134 3.44
> = 14 5639 43 49 1.14 48 1.12 144 3.35
Age at first live birth, y <20 1091 9 7 0.78 0.181 7 0.78 0.370 24 2.67 < 0.001
20-24 6393 45 53 1.18 50 1.11 151 3.36
25-29 4200 30 42 1.40 38 1.27 104 3.47
>29 1003 14 13 0.93 11 0.79 32 2.29
No
children
925 10 9 0.90 9 0.90 30 3.00
Body mass index <25 3439 24 32 1.33 0.200 27 1.13 0.470 85 3.54 < 0.001
25-29 4624 32 42 1.31 40 1.25 118 3.69
30-34 1997 19 18 0.95 19 1.00 53 2.79
> = 35 691 5 6 1.20 7 1.40 19 3.80
Breast density (BI-RADS)(1) 1 3019 21 27 1.29 0.063 18 0.86 0.080 37 1.76 < 0.001
2 5480 36 49 1.36 42 1.17 131 3.64
3 2421 29 22 0.76 26 0.90 81 2.79
4 2140 17 19 1.12 29 1.71 72 4.24
No. of biopsies 0 13588 108 123 1.14 - 113 1.05 - 339 3.14 -
> = 1 121 0 1 - 1 - 4 -
Affected first-degree
relatives
No 12949 97 111 1.14 0.149 105 1.08 0.605 317 3.27 < 0.001
Yes 730 10 13 1.30 10 1.00 23 2.30
Previous benign breast
disease
No 12712 98 115 1.17 0.162 105 1.07 0.754 307 3.13 < 0.001
Yes 997 10 9 0.90 9 0.90 36 3.60
(1)1: Almost entirely fat, 2: Scattered fibroglandular densities, 3: Heterogeneously dense, 4: Extremely dense.
(2)The p-values shown in the table correspond to the Hosmer-Lemeshow C statistic. All the p-values for the chi-square test for trend were higher than 0.1.
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tained an AUC of 0.561 for the Gail model and 0.586 for
the Chen model, for the same 5-year period. Actually,
the confidence intervals of the area under the curve in
our study contained the values of the original models.
The original Barlow publication only showed the dis-
criminatory value of the one-year predictive model,
0.624 [12]. In our study, this figure was 0.602 and the
95% CI (0.440, 0.765) also included the original AUC
value.
At the European level, there are adaptations of the
Gail model in concrete populations such as an Italian
and a Spanish study [26,27]. One important aspect of
these studies is that they include relative risks of the risk
factors adapted to their study population. Furthermore,
they also modify the incidence of BC as well as mortality
by other causes. The risk factors included and the meth-
odology applied for the projection of risks at five years
was exactly the same as that used in the original Gail
model. Discrimination levels of the Italian and the Spanish
adapted models were 0.590 and 0.544, respectively. In the
Italian study, the AUC was similar to the 0.586 that Gail
found in his study population, whereas in the Spanish
study, the AUC was lower and similar to our estimate.
Another article published in the US [28] showed that
the use of relative risks specific to Hispanic and non-
Hispanic populations slightly improved discrimination.
In our study, the relative risks were not estimated using
the study population due to small frequencies in some
of the groups defined by risk factors. Although the
original relative risks seem to work well for the Gail and
Chen models, they may explain in part the lack of
calibration of the Barlow model.
Other facts that can explain why the Barlow model
did not perform well are differences in the population
characteristics, inclusion criteria, and timing projec-
tions. In contrast to our study sample, women included
in the Barlow study were racially and ethnically diverse.
The Barlow study sample included the incident cases
detected by the first mammogram and was developed as
a short-time prediction model. Additionally, the model
does not use BC incidence rate or mortality by other
causes. All these facts also may explain why the Barlow
model overestimates risk of breast cancer in our popula-
tion. A new model for assessing 5-year risk was developed
later by the Breast Cancer Surveillance Consortium [29],
which would be interesting to assess in a Spanish popula-
tion in future studies.
In Darabi et al. [30], where the Gail model was evaluated
using data from a Swiss study, the result was an AUC and
95% confidence interval of 0.548 (0.527, 0.568). Further-
more, they determined the improvement in prediction due
to the incorporation of breast density and body mass
index. The expanded model increased the AUC to 0.571(0.545, 0.597). Our results show that the Chen and Barlow
models, that also incorporate breast density, have slightly
greater discriminatory power for prediction at five years
than the Gail model.
We have identified three published studies in which one
of the studied models, the Gail model, was applied to the
Spanish population. Pastor-Climente et al. [31] estimated
the risk of developing BC in a 5-year period, using the Gail
model calculator available on the web, without adapting
either incidence or mortality for other causes [32]. The
sample used included only women that had been diag-
nosed with BC. The study concluded that only 42% of
women diagnosed with BC had a high risk, defined as
1.67% or greater [18]. Thus, the original Gail model
showed low sensitivity, and sensitivity is a required
characteristic for a model to be used for decision-
making in a screening context. Buron et al. [33], in a
screening program context, assessed the utility of the
original Gail model to predict BC in women with a prior
positive mammogram. At five years, discrimination was
low (AUC = 0.61) and, using the standard threshold of
1.67%, sensitivity and specificity were 46.2% and 72.1%,
also too low for clinical decision-making. The third
study, by Pastor Barriuso et al. [27], assessed the per-
formance of the original and a recalibrated Gail model
together with a new model fully developed by the au-
thors. Consistent with our results, the recalibrated Gail
model was well calibrated overall, although it tended to
underestimate risk for women in low-risk quintiles and
to overestimate it in high-risk quintiles. In our study, we
observed concordance between expected and observed in
the low-risk groups and a slight overestimation of risk in
high-risk quintiles.
Breast density is a risk factor strongly associated with
the risk of BC, as demonstrated in recent years in vari-
ous studies [34,35]. The Chen model was designed as an
adaptation of the Gail model with the incorporation of
breast density as a risk factor. If we compare the results
obtained in our study, we see that the Chen model shows
improved discrimination at five years over the Gail model,
although in our sample the Chen model overestimates risk
for women with high density. The Chen model used a
quantitative measure of density, although it was then cate-
gorized into a variable with five categories, similar to the
BI-RADS classification. Given the significant correlation
between the BI-RADS and other quantitative measure-
ment systems [36,37], and the availability of the BI-RADS
in our screening program, we considered using it as an
approximation. Nevertheless, the inclusion of longitu-
dinal measurements of breast density in the models
could improve the risk estimates, as other authors have
shown [38].
Another risk factor with important weight in these
models is family history. The coefficient of the Barlow
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model’s coefficient for the variable “number of first-degree
relatives with BC”. Nevertheless, the Barlow model for
post-menopausal women has a lower coefficient. It is pos-
sible that part of the risk attributable to family history is
explained by other variables, such as body mass index or
surgical menopause, which are not included in the other
models mentioned. The Gail model, on the other hand,
gives a higher weight to family history in comparison
to the Chen model. With the inclusion of breast density
in the model, family history loses its impact in risk
prediction.
One of the principal contributions of our study is the
assessment of the risk models using specific incidence
and mortality rates by birth cohort in our geographic
area. This procedure makes it possible to improve the
Gail and Chen estimates based on the incidence rates of
BC and mortality rates by other causes, which were ob-
tained from a cross-sectional study. Given that BC inci-
dence rates have an increasing trend, cross-sectional rates
overestimate rates for past periods and underestimate
those of future periods. As a result of using mortality rates
by birth cohort, estimated survival in women over 50 in
our study increased considerably in comparison with the
US data of the original models. Therefore, a conclusion of
our study was that, when local data for BC incidence and
mortality from other causes were used, the Gail and Chen
models provided unbiased estimates of risk of developing
BC in our population.
One limitation of this study is that the Girona and
Tarragona Cancer Registries do not include the population
in the area studied. Although there were no differences ob-
served in incidence rates between Girona and Tarragona,
two areas of Catalonia that are geographically separated,
it may be that the study area had a lower incidence of
BC. Nevertheless, in a previous study, no differences
were observed in BC mortality between a geographical
region that included the study population, and the prov-
inces of Girona and Tarragona [39].
Other limitations are related to the number of cancer
cases and to missing values. As mentioned above, the
small number of cancer cases precluded estimating
specific relative risks, which have an impact on the
performance of the models, along with the incidence
and mortality rates. With respect to missing values, a
sensitivity analysis with complete data showed that the
calibration results were similar and discrimination
slightly improved.
Finally, it is worth mentioning that the risk estimates
are based only on the baseline characteristics reported at
the first screening exam of the early detection program.
With the number of previous biopsies being an important
risk factor, a very small number of women reported having
had biopsies before their first screening mammography. Inthese risk models, this is an important issue, because the
estimating equation assumes that the probability or the
relative risk is maintained over time.
Conclusion
In conclusion, this work showed that using local data on
BC incidence and mortality from other causes, appropriate
group risk estimates for the Gail and Chen models can be
obtained. Nevertheless, the three studied risk models do
not have discriminatory power in our setting and there-
fore, they cannot be used as a measure of individual risk
in early detection programs to customize screening
strategies. More work is necessary in this field for
obtaining reliable tools to estimate individual risk. The
inclusion of longitudinal measures of breast density or
other risk factors in joint models of survival and longi-
tudinal data may be a step towards personalized early
detection of BC.
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